ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

amgen europe b.v. - romiplostim - purpura, trombocitopēnija, idiopātija - antihemorāģija - adults:nplate is indicated for the treatment of primary immune thrombocytopenia  (itp) in adult patients who are refractory to other treatments (e. kortikosteroīdi, imūnglobulīni). paediatrics:nplate is indicated for the treatment of chronic primary immune thrombocytopenia (itp) in paediatric patients one year of age and older who are refractory to other treatments (e. kortikosteroīdi, imūnglobulīni).

ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloksetīna hidrohlorīds - urīna nesaturēšana, stresa - psychoanaleptics, - yentreve indicēts sievietēm vidēji smagas vai smagas stresa urīna nesaturēšanas gadījumā (sui).

ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

grunenthal gmbh - capsaicin - neiralģija - anestēzijas līdzekļi - qutenza ir indicēts perifēro neiropātisku sāpju ārstēšanai pieaugušajiem vai nu atsevišķi, vai kombinācijā ar citām zālēm sāpēm.

ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

esteve pharmaceuticals, s.a. - duloxetine - anxiety disorders; depressive disorder, major; diabetic neuropathies - psychoanaleptics, - attieksmi pret depresiju;Ārstēšana diabētiskās perifērās neiropātijas sāpju;Ārstēšana vispārēja trauksme;xeristar ir norādīts pieaugušie.

ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

elanco gmbh - vieglāks - ectoparasiticides līdzekļi sistēmiskai lietošanai, isoxazolines - dogs; cats - par attieksmi pret blusu un ērču invāzijas. blusas un ērces ir jāpievieno mītnes un sāk barot, lai būtu pakļauti aktīvās vielas. veterinārās zāles var izmantot kā daļu no blusu alerģiskā dermatīta (fad) ārstēšanas stratēģijas.. dogsthis veterinārās zāles, kas nodrošina tūlītēju un noturīgu nogalināšanu darbības uz 1 mēnesi par blusu (ctenocephalides felis) un c. canis) un ērču (rhipicephalus sanguineus, ixodes ricinus, es. hexagonus un dermacentor reticulatus). catsthis veterinārās zāles, kas nodrošina tūlītēju un noturīgu nogalināšanu aktivitāte 1 mēnesi, pret blusu (ctenocephalides felis) un c. canis) un ērču (ixodes ricinus).

ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multiplā skleroze - selective immunosuppressants - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

ইউরোপীয় ইউনিয়ন - লাত্‌ভীয় - EMA (European Medicines Agency)

roche registration gmbh - atezolizumabs - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastiski līdzekļi - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kā monotherapy ir norādīts ārstēšanai pieaugušiem pacientiem ar lokāli papildu vai metastātiska nsclc pēc iepriekšējas ķīmijterapijas. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kā monotherapy ir norādīts ārstēšanai pieaugušiem pacientiem ar lokāli papildu vai metastātiska nsclc pēc iepriekšējas ķīmijterapijas. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

desitin arzneimittel gmbh, germany - retinoli palmitas, int-rac-alfa-tocopherylis acetas - deguna pilieni, šķīdums

লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

uab bayer, lithuania - dekspantenols - krēms - 50 mg/g

লাত্ভিয়া - লাত্‌ভীয় - Zāļu valsts aģentūra

pharmaceutical laboratory labofarm, poland - allii sativi spuldzes - tablete - 300 mg